- ICH GCP
- Registro de ensayos clínicos de la UE
Últimos ensayos
EudraCT Number: 2018-001771-21 | Sponsor Protocol Number: XL184–311 | Start Date: | |||||||||||
Sponsor Name: Exelixis, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-... | |||||||||||||
Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) FR (Ongoing) AT (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002012-23 | Sponsor Protocol Number: SL79.22 | Start Date: | |||||||||||
Sponsor Name: STALLERGENES | |||||||||||||
Full Title: A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-in... | |||||||||||||
Medical condition: Birch Pollen-induced Allergic Rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) FR (Ongoing) FI (Ongoing) DE (Ongoing) LT (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing) AT (Ongoing) LV (Ongoing) PL (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004704-38 | Sponsor Protocol Number: GBG70 | Start Date: | |||||||||||
Sponsor Name: GBG Forschungs GmbH | |||||||||||||
Full Title: Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with lo-cally advanced or operable breast cancer receiving taxane-anthracycline containing chemo-therapy (DAFNE st... | |||||||||||||
Medical condition: Patients with HER2-positive early breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004904-50 | Sponsor Protocol Number: GWEP15100 | Start Date: | |||||||||||
Sponsor Name: GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. | |||||||||||||
Medical condition: Infantile Spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005375-91 | Sponsor Protocol Number: NN9535-4216 | Start Date: | |||||||||||
Sponsor Name: Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FI (Completed) DE (Completed) GB (Completed) SK (Completed) LV (Completed) LT (Completed) GR (Completed) ES (Completed) PT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022923-31 | Sponsor Protocol Number: FIinTIC | Start Date: | |||||||||||
Sponsor Name: Medizinische Universität Innsbruck / Univ.-Klinik für Allgem. u. Chirurg. Intensivmedizin | |||||||||||||
Full Title: A multicenter double-blind, placebo controlled, randomized, pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients, presumed to bleed ... | |||||||||||||
Medical condition: Trauma patients with major bleeding or occult bleeding who received volume replacement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000214-42 | Sponsor Protocol Number: 755-201-EB | Start Date: | |||||||||||
Sponsor Name: InMed Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa. | |||||||||||||
Medical condition: Epidermolysis bullosa | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) GR (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001624-14 | Sponsor Protocol Number: LE3301 | Start Date: | |||||||||||
Sponsor Name: Pharming Technologies B.V. | |||||||||||||
Full Title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kina... | |||||||||||||
Medical condition: Activated Phosphoinositide 3-Kinase Delta Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004988-30 | Sponsor Protocol Number: 23386753 | Start Date: | ||||||
Sponsor Name: Mater Misercordiae Hospital - Department of Anaesthesia | ||||||||
Full Title: PHARMACOKINETICS AND ANALGESIC EFFICACY OF LAEVOBUPIVACAINE, FENTANYL AND CLONIDINE FOR POSTOPERATIVE PARAVERTEBRAL ANAESTHESIA. | ||||||||
Medical condition: We are aiming to provide postoperative analgesia for breast surgery | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: IE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017347-33 | Sponsor Protocol Number: Clofarabine | Start Date: | ||||||||||||||||
Sponsor Name: University of Leipzig | ||||||||||||||||||
Full Title: A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy | ||||||||||||||||||
Medical condition: Acute myeloid leukaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |